Renal cell carcinoma (RCC) is the most common renal cancer and constitutes a significant burden of disease. Tumor thrombus is present in approximately 10% of cases at initial diagnosis and impacts the morbidity and mortality of the disease. The primary treatment for RCC involves resection of the tumor. The presence of tumor thrombus, therefore, is not only important for prognosis but also for operative planning. Operative approach, including vascular control and caval closure are important consideration when resecting RCC with inferior vena cava (IVC) tumor thrombus and varies based on the patient presentation, extent of the tumor, and the surgeon’s experience. This article presents a patient with RCC with IVC thrombus who ultimately underwent surgical resection with general surgery, vascular surgery, and urology to showcase the multidisciplinary care, surgical considerations, and current management and treatment strategies for RCC with tumor thrombus.
AlmatariAL, SatheA, WidemanL, et al.Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist. Urol Oncol, 2023; 41(4):153–165; doi: 10.1016/j.urolonc.2022.11.021
4.
MsaouelP, GenoveseG, TannirNM. Renal cell carcinoma of variant histology: Biology and therapies. Hematol Oncol Clin North Am, 2023; 37(5):977–992; doi: 10.1016/j.hoc.2023.04.019
5.
CapriniJA, ArcelusJI, HastyJH, et al.Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost, 1991; 17(Suppl 3):304–312.
6.
CapitanioU, BensalahK, BexA, et al.Epidemiology of renal cell carcinoma. Eur Urol, 2019; 75(1):74–84; doi: 10.1016/j.eururo.2018.08.036
7.
AdibiM, ThomasAZ, BorregalesLD, et al.Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol, 2015; 33(12):528–537; doi: 10.1016/j.urolonc.2015.10.003
8.
VidartA, FehriK, PfisterC. Metastases inhabituelles du cancer du rein [Unusual metastasis of renal carcinoma]. Ann Urol (Paris), 2006; 40(4):211–219; doi: 10.1016/j.anuro.2006.03.004
9.
DasonS, MohebaliJ, BluteML, et al.Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Urol Clin North Am, 2023; 50(2):261–284; doi: 10.1016/j.ucl.2023.01.007
10.
SethA. Management of IVC thrombus-surgical strategies and outcomes. Indian J Surg Oncol, 2017; 8(2):156–159; doi: 10.1007/s13193-016-0583-4
11.
QuencerKB, FriedmanT, ShethR, et al.Tumor thrombus: Incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther, 2017; 7(Suppl 3):S165–S177; doi: 10.21037/cdt.2017.09.16
12.
BluteML, LeibovichBC, LohseCM, et al.The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int, 2004; 94(1):33–41; doi: 10.1111/j.1464-410X.2004.04897.x
13.
MastorakiA, MastorakiS, Tsikala-VafeaM, et al.Prognostic benefit of surgical management of renal cell carcinoma invading the inferior vena cava. Indian J Surg Oncol, 2017; 8(1):14–18; doi: 10.1007/s13193-016-0528-y
14.
BamiasA, EscudierB, SternbergCN, et al.Current clinical practice guidelines for the treatment of renal cell carcinoma: A systematic review and critical evaluation. Oncologist, 2017; 22(6):667–679; doi: 10.1634/theoncologist.2016-0435
15.
AitchisonM, BrayCA, Van PoppelH, et al.Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer, 2014; 50(1):70–77; doi: 10.1016/j.ejca.2013.08.019
16.
MandhaniA, PatidarN, AgaP, et al.A new classification of inferior vena cava thrombus in renal cell carcinoma could define the need for cardiopulmonary or venovenous bypass. Indian J Urol, 2015; 31(4):327–332; doi: 10.4103/0970-1591.166459
17.
KanitraJ, HoltropJ, JawadA, et al.Extended duration chemoprophylaxis for venous thromboembolism following abdominopelvic oncologic surgery. J Thromb Thrombolysis, 2020; 50(1):190–194; doi: 10.1007/s11239-019-02002-9
18.
ChenYW, WangL, PanianJ, et al.Treatment landscape of renal cell carcinoma. Curr Treat Options Oncol, 2023; 24(12):1889–1916; doi: 10.1007/s11864-023-01161-5
19.
ChoueiriTK, TomczakP, ParkSH, et al.; KEYNOTE-564 Investigators. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med, 2021; 385(8):683–694; doi: 10.1056/NEJMoa2106391
20.
PadalaSA, BarsoukA, ThandraKC, et al.Epidemiology of renal cell carcinoma. World J Oncol, 2020; 11(3):79–87; doi: 10.14740/wjon1279
21.
KlatteT, RossiSH, StewartGD. Prognostic factors and prognostic models for renal cell carcinoma: A literature review. World J Urol, 2018; 36(12):1943–1952; doi: 10.1007/s00345-018-2309-4
22.
TaweemonkongsapT, Suk-OuichaiC, JitpraphaiS, et al.Survival benefits after radical nephrectomy and IVC thrombectomy of renal cell carcinoma patients with inferior vena cava thrombus. Heliyon, 2024; 10(4):e25835; doi: 10.1016/j.heliyon.2024.e25835
